SBC Medical Group (SBC) reported $174M in revenue for fiscal 2025, −15.5% year on year. That ranks #2722 by revenue among 2853 SEC filers and #299 in Healthcare. Net income was $51.0M, a net margin of 29.4%. Revenue has declined 5.3% a year on average since 2023 ($194M then). The fiscal 2025 balance sheet shows $380M in total assets, $164M in cash and $42.8M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $174M | −15.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $127M | −18.4% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $67.5M | −4.0% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $51.0M | +9.4% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $24.7M | +19.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.4M | −45.4% | FY20252025-12-31 |
| Total assetsAssets | $380M | +43.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $248M | +27.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $164M | +31.0% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $42.8M | +549.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $43.1M | $11.3M | Open → |
| Q2 20262026-06-30 | $49.2M | $10.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- SBC Medical Group Holdings Inc
- Ticker
- SBC
- Exchange
- Nasdaq
- SIC classification
- Services-Offices & Clinics of Doctors of Medicine (8011)
- Fiscal year end
- 12-31
- CIK
- 0001930313
Filings
- 10-QAug 13, 2026Open filing →
- 10-QMay 14, 2026Open filing →
- 10-KMar 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| CryoportCYRX | $176M | $78.3M |
| HeartflowHTFL | $176M | −$117M |
| Phathom PharmaceuticalsPHAT | $175M | −$221,250 |
| SBC Medical GroupSBC | $174M | $51.0M |
| Syndax PharmaceuticalsSNDX | $172M | −$285M |
| RegenxbioRGNX | $170M | −$194M |
| Ginkgo BioworksDNA | $170M | −$313,000 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=SBC Medical Group — Key figures |url=https://companiesranked.com/en/company/sbc-medical-group |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). SBC Medical Group — Key figures. CompaniesRanked. https://companiesranked.com/en/company/sbc-medical-groupBibTeX
@misc{companiesranked-en-company-sbc-medical-group-2026,
author = {{CompaniesRanked}},
title = {{SBC Medical Group — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/sbc-medical-group}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-127557 · March 27, 2026
{{cite web |title=SBC Medical Group — Key figures — 10-K (0001193125-26-127557) |url=https://www.sec.gov/Archives/edgar/data/1930313/000119312526127557/sbc-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.